Available Technologies

Browse Penn-owned technologies available for licensing.


A New Approach to Treat Neurodegenerative Diseases



Technology Overview


Aberrant protein folding is severely problematic and manifests in numerous disorders, including amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), Huntington disease (HD), and Alzheimer disease (AD). Patients with each of these disorders are characterized by the accumulation of mislocalized protein deposits. Treatments for these disorders remain palliative, and no available therapeutic eliminates the underlying toxic conformers.


An intriguing approach to reverse deleterious protein misfolding is to upregulate chaperones to restore proteostasis. Dr. Shorter and his team recently re-engineered a prion disaggregase from yeast, Hsp104, to reverse protein misfolding implicated in human disease. These potentiated Hsp104 variants suppress TDP-43, FUS, and α-synuclein toxicity in yeast, eliminate aggregates, reverse cellular mislocalization, and suppress dopaminergic neurodegeneration in an animal model of PD. 




• Reverses of protein aggregation

• Restores protein function, ie, normal functionality


Stage of Development

In vivo experiments 

Intellectual Property

US 9,994,625


Reference Media

Jackrel, MR et al.; Cell 2014 Jan 156(1-2) 170


Desired partnerships

• License

• Sponsored research


Docket # 14-7014 


Download pdf

Patent Information:
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
James Shorter
Meredith Jackrel
Neurodegenerative Diseases
Neurological Disorders